Literature DB >> 15554691

Generalization of a targeted library design protocol: application to 5-HT7 receptor ligands.

Erik Nordling1, Evert Homan.   

Abstract

Herein a general concept for the design of targeted libraries for proteins with binding sites that are divided into subsites is laid out, including several practical aspects and their solutions. The design is based on a chemogenomic classification of the subsites followed by collection of bioactive molecular fragments and virtual library generation. The general process is outlined and applied to the assembly of a library of 500 molecules targeting the serotonin type 7 (5-HT7) receptor, a class A G-Protein Coupled Receptor (GPCR). Utilizing commercially available building blocks of similar size and composition, a reference library was created. Control sets of known ligands for the 5-HT7 receptor, other GPCRs, and nuclear receptors were collected from literature sources. Principal component analysis of molecular descriptors for the two libraries and the literature sets, displayed a focusing of the targeted library to the region in the chemical space defined by the literature actives, suggesting a denser coverage of the bioactive region than for the more diverse reference library. Additional computational validations, including PCA class predictions, 3D pharmacophore modeling, and docking calculations all indicated an enrichment factor of 5-HT7 ligand-like molecules in the range of 2-4 for the targeted library compared to the reference library.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554691     DOI: 10.1021/ci049822w

Source DB:  PubMed          Journal:  J Chem Inf Comput Sci        ISSN: 0095-2338


  1 in total

1.  Phe369(7.38) at human 5-HT(7) receptors confers interspecies selectivity to antagonists and partial agonists.

Authors:  Thibault Varin; Hugo Gutiérrez-de-Terán; Marián Castro; José Brea; Frederic Fabis; François Dauphin; Johan Aqvist; Alban Lepailleur; Pilar Perez; Javier Burgueño; José Miguel Vela; Maria Isabel Loza; Jordi Rodrigo
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.